## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence as presented in the abstract; no access to full manuscript, figures, tables, or supplementary materials
- **Shared manuscript claim summary** The study investigates associations between genetic polymorphisms in MGMT and ERCC1 genes and clinical outcomes in North Indian lung cancer patients treated with platinum-based doublet chemotherapy, using PCR-RFLP genotyping, statistical survival analysis, and computational methods including molecular dynamics simulation and docking. The authors report significant associations between specific genotypes and survival, and computational results suggesting that a mutated MGMT protein is more stable but binds DNA less effectively than the wild-type.
- **Visible evidence base** Abstract text only; specific numerical results for hazard ratios, p-values, RMSD, radius of gyration, RMSF, and docking scores are reported without methodological detail or data presentation
- **Missing materials affecting confidence** Full manuscript text, all figures and tables, detailed methods for genotyping and statistical analysis, MD simulation parameters, docking methodology, validation procedures, patient cohort characteristics, and ethical approvals

## Reviewer
- **Overall assessment** The abstract presents a potentially interesting translational study combining clinical genotyping with computational structural analysis. However, the evidence as presented is insufficient to evaluate the robustness of the statistical associations or the validity of the computational conclusions. Several critical methodological details are absent, and some reported results appear internally inconsistent. The clinical and computational components are not clearly integrated, and the abstract does not provide enough information to assess whether the conclusions are supported by the data.
- **Who would be interested in the results, and why** Researchers in pharmacogenomics and personalized oncology would be interested in the potential predictive value of MGMT and ERCC1 polymorphisms for platinum-based chemotherapy outcomes. Computational biologists studying DNA repair protein dynamics and DNA binding may find the structural analysis of the MGMT L84F variant of interest. Clinicians managing lung cancer patients in populations with similar genetic backgrounds might also find the survival associations relevant, though the clinical utility remains uncertain.
- **Major strengths** The study addresses a clinically relevant question regarding genetic predictors of chemotherapy response. The combination of clinical genotyping with computational structural analysis is an ambitious integrative approach. The focus on a North Indian population may contribute to diversity in pharmacogenomic data. The use of multiple computational methods, including MD simulation and docking, provides a multi-faceted view of the mutant protein behavior.
- **Major Concerns**
  - **Concern ID** R1-M1
  - **Severity** Major
  - **Blocking** Yes
  - **Axis** Statistical validity and interpretation
  - **Claim pointer** The abstract claims significant associations between MGMT and ERCC1 polymorphisms and survival outcomes, reporting hazard ratios and p-values for various genotype comparisons.
  - **Evidence pointer** Abstract results section; location not provided
  - **Concern** The reported hazard ratios and p-values are presented without confidence intervals, multiple testing corrections, or details on the statistical models used. The direction of effect for ERCC1 combined variants in ADCC patients is inconsistent, with HR=1.25 for mutant and HR=0.78 for combined variants, yet both are reported as significant. This apparent contradiction is not explained. Additionally, the abstract does not specify which genetic model was applied, how many comparisons were made, or whether adjustments for covariates such as age, sex, smoking status, or disease stage were performed.
  - **Why it matters** Without proper statistical reporting and correction for multiple comparisons, the reported associations may be false positives. The inconsistent hazard ratios for ERCC1 variants raise concerns about the reliability of the analysis. The clinical conclusion that these polymorphisms are associated with decreased overall survival cannot be accepted without robust statistical evidence.
  - **Resolution test** Provide full statistical details including confidence intervals, model specifications, covariate adjustments, and multiple testing corrections. Clarify the discrepancy between the ERCC1 mutant and combined variant hazard ratios. If the combined variant analysis includes different genotype groupings, this must be explicitly defined and justified.
  - **Concern ID** R1-M2
  - **Severity** Major
  - **Blocking** Yes
  - **Axis** Computational methodology and validation
  - **Claim pointer** The abstract claims that MD simulation results demonstrate the mutated MGMT protein is more stable than the wild-type, and that docking scores indicate the mutant binds DNA less effectively.
  - **Evidence pointer** Abstract results section; location not provided
  - **Concern** The abstract reports RMSD, radius of gyration, and RMSF values without specifying the simulation length, force field, water model, temperature, pressure coupling, or the number of replicates. The docking scores are presented as single values without information on the docking software, scoring function, or whether multiple conformations were sampled. No error estimates or statistical comparisons between wild-type and mutant simulations are provided. The claim that the mutant "cannot bind properly to DNA" is a strong functional conclusion drawn from computational data alone, without experimental validation.
  - **Why it matters** Molecular dynamics and docking results are highly sensitive to simulation parameters and analysis choices. Without detailed methodology and validation, the computational conclusions cannot be reproduced or assessed for reliability. The functional interpretation that the mutant cannot repair DNA properly is a mechanistic claim that requires experimental support or at least more rigorous computational evidence.
  - **Resolution test** Provide complete simulation and docking parameters, including software versions, force fields, simulation times, equilibration protocols, and analysis methods. Include error bars or replicate simulations. Discuss the limitations of computational predictions and, if possible, provide experimental validation or clearly frame the computational results as hypothesis-generating rather than conclusive.
  - **Concern ID** R1-M3
  - **Severity** Major
  - **Blocking** Yes
  - **Axis** Integration of clinical and computational findings
  - **Claim pointer** The abstract concludes that MGMT and ERCC1 polymorphisms are associated with decreased overall survival and that computational analysis of MGMT (rs12917) reveals the mutated protein cannot properly repair DNA, resulting in lower overall survival.
  - **Evidence pointer** Abstract conclusion; location not provided
  - **Concern** The abstract does not establish a direct link between the computational findings and the clinical outcomes. The MD and docking analyses were performed on MGMT rs12917, but the clinical associations were reported for MGMT and ERCC1 genotypes without specifying which polymorphisms were analyzed. It is unclear whether the rs12917 variant is the same polymorphism associated with survival in the clinical cohort. The causal chain from computational stability and binding predictions to clinical survival outcomes is not supported by the presented evidence.
  - **Why it matters** The conclusion that the mutated MGMT cannot repair DNA and therefore leads to lower survival is a mechanistic claim that requires demonstration that the specific variant studied computationally is the same variant associated with clinical outcomes, and that the computational predictions translate to functional consequences in patients. Without this integration, the two components of the study remain disconnected.
  - **Resolution test** Clearly specify which MGMT and ERCC1 polymorphisms were genotyped and which were used in computational analyses. Demonstrate that the rs12917 variant is the clinically associated polymorphism. Provide a reasoned argument or additional data linking computational predictions to clinical outcomes, or temper the conclusion to reflect the separate nature of the findings.
- **Minor Comments**
  - **Concern ID** R1-m1
  - **Severity** Minor
  - **Axis** Clarity and completeness of reporting
  - **Affected element** Patient cohort description
  - **Evidence pointer** Abstract introduction and methods; location not provided
  - **Issue** The abstract states the study examines lung cancer patients of North Indian descent but does not provide the sample size, sex distribution, age range, or histological subtypes. The abbreviation "ADCC" is used without definition, and it is unclear whether this refers to a patient subgroup or a different entity.
  - **Required correction** Define all abbreviations at first use. Provide basic cohort characteristics including sample size and key demographic and clinical features.
  - **Concern ID** R1-m2
  - **Severity** Minor
  - **Axis** Technical accuracy
  - **Affected element** Genotyping method description
  - **Evidence pointer** Abstract methods; location not provided
  - **Issue** The abstract states "P CR-RFLP method was used" which appears to be a typographical error for "PCR-RFLP." This should be corrected for accuracy.
  - **Required correction** Correct the typographical error to "PCR-RFLP."
  - **Concern ID** R1-m3
  - **Severity** Minor
  - **Axis** Interpretation of computational results
  - **Affected element** MD simulation interpretation
  - **Evidence pointer** Abstract results; location not provided
  - **Issue** The abstract states that lower RMSD, stable radius of gyration, and lower RMSF indicate the mutated protein is more stable. While this is a common interpretation, it is not universally accepted that lower RMSD alone indicates greater functional stability, and the biological relevance of these metrics should be discussed.
  - **Required correction** Provide a more nuanced interpretation of the MD metrics and discuss their biological significance in the context of protein function.
  - **Concern ID** R1-m4
  - **Severity** Minor
  - **Axis** Reporting of docking results
  - **Affected element** Docking score interpretation
  - **Evidence pointer** Abstract results; location not provided
  - **Issue** The docking scores are reported as -201.6 and -131.8 for DNA-Wild and DNA-L84F mutants, respectively. The units and the meaning of these scores are not specified, and it is unclear whether lower or higher scores indicate better binding in the software used.
  - **Required correction** Specify the docking software, the scoring function, and the interpretation of the scores. Provide context for whether the difference is significant.
- **Technical failings that need to be addressed before the case is established** R1-M1, R1-M2, R1-M3. The statistical analysis lacks essential details and contains an apparent inconsistency. The computational methodology is underreported and the functional conclusion is not supported by the evidence presented. The clinical and computational components are not clearly linked.

## Assessment against Nature-style criteria
- **Originality** The combination of clinical genotyping with MD simulation and docking for MGMT and ERCC1 in a North Indian population has some novelty, but the general approach of correlating DNA repair gene polymorphisms with chemotherapy outcomes is well established. The computational analysis of a specific MGMT variant adds a structural dimension that is not commonly included in pharmacogenomic studies.
- **Scientific importance** The potential to identify genetic predictors of platinum-based chemotherapy response is clinically relevant. However, the importance is diminished by the lack of robust statistical evidence and the absence of validation. The findings, as presented, are preliminary and would not change clinical practice.
- **Interdisciplinary readership** The study bridges clinical oncology, pharmacogenomics, and computational structural biology, which could appeal to readers across these fields. However, the abstract does not provide sufficient detail for any single discipline to fully evaluate the work.
- **Technical soundness** The technical soundness cannot be assessed from the abstract alone. The statistical methods are underreported, the computational parameters are not specified, and the integration of results is not demonstrated. The apparent inconsistency in ERCC1 hazard ratios raises concerns about the analysis.
- **Readability for nonspecialists** The abstract is generally readable but uses technical terms without adequate explanation. The abbreviation "ADCC" is undefined, and the computational metrics are presented without context. The logical flow from results to conclusions is not always clear.

## Recommendation posture
Currently not established from the provided evidence. The abstract presents potentially interesting findings, but the statistical analysis is incomplete and contains an apparent inconsistency, the computational methodology is underreported, and the link between the clinical and computational components is not demonstrated. The manuscript would require substantial revision and additional information before the claims could be considered supported. A supportive recommendation would be contingent on addressing the major concerns regarding statistical rigor, computational methodology, and integration of findings.

## Risk / unsupported claims
- The claim that MGMT and ERCC1 polymorphisms are associated with decreased overall survival is unsupported due to incomplete statistical reporting and an apparent inconsistency in the ERCC1 hazard ratios.
- The claim that the mutated MGMT protein is more stable than the wild-type is unsupported without detailed MD simulation parameters and error analysis.
- The claim that the mutated MGMT cannot bind properly to DNA and therefore cannot properly repair DNA is unsupported, as it is based on computational predictions without experimental validation and without demonstrating that the computationally studied variant is the clinically associated polymorphism.
- The causal link between computational findings and clinical survival outcomes is not established and should not be stated as a conclusion.